Application of circulating tumor cells scope technique on circulating tumor cell research
© Yang et al.; licensee BioMed Central Ltd. 2014
Received: 16 October 2013
Accepted: 10 February 2014
Published: 10 March 2014
Circulating tumor cells (CTCs) are becoming promising biomarkers in several cancers, such as colon, prostate, and breast carcinomas. Independent research groups have reported a correlation between CTC numbers and patient prognosis. Even more, the development of personalized medicine gives physicians impetus to utilize the advancement of molecular characterization of CTCs. This review introduces a new technique, CTCscope, and compares it with the current methods of CTCs detection, with particular emphasis on cancer research, and discusses the future application of this new method from bench to bed-side.
KeywordsCTCs ISH qRT-PCR CTCscope
Comparison of current CTC enrichment and detection method with CTCscope technique
Density of mononuclear cells (Ficoll centrifugation)
RNA ISH (Multiplex CTC specific mRNA)
Less blood sample
Not easy to perform in a clinical lab
Simple technique; EpCAM-negative cells can be isolated
Payne et al. 2012 
Immunomagnetic enrichment of EpCAM-positive cells
IHC (CKs, CD45, DAPI)
Moderate; low in EpCAM negative cases
At least 7.5 mL blood sample
Live or dead cells
Cannot identify EpCAM-negative CTCs (such as tumour stem cells with estrogen receptor negative phenotype in breast cancers); expensive;
Easy to use semiautomated system; reproducibility; only assay approved by FDA
Peeters et al. 2013 
Detected only viable CK19-releasing
RNA isolation and multiplex PCR for tumour-specific transcripts (MUC1+/HER2+/EpCAM+)
MUC1 is also expressed on activated T lymphocytes; Semiquantitative PCR
Enables the additional analysis of transcripts
Tewes et al. 2009 
At least 7.5 mL blood sample
No impact on the transcriptional profile of single cancer cell isolated
Talasaz et al. 2009 
Immunoflurorescent detection of antigen expression
Dependent on expression of epithelial or tumor markers
Further characterization (FACS); multiple antibodies; morphology evaluation
Lu et al. 2010 
In vivo study, Burd et al. used standard homologous recombination procedures to target firefly luciferase on the SV40 polyadenylation site to exon 1α of the endogenous p16INK4a gene . Then they applied RNA in situ hybridization (ISH) by using RNAscope 2.0 technology to detect this faithfully reports expression gene, which serves as a tumor suppressor and aging biomarker. Their work suggests that p16INK4a activation is a characteristic of all emerging cancers and it could be set as a sensitive, unbiased reporter of neoplastic transformation. While in situ RNA study, Staudt et al. applied macrophage inflammatory protein-1a/CCL3-specific RNA target probe set, which targeted nucleotides 23 to 771 of the CCL cDNA sequence to detect CCL3 mRNA in tumor samples . CCL3 is a chemokine, which is known to amplify inflammation. They found inhibiting NF-ҡB reversed the increase in CCL3 expression associated with LDL receptor-related protein (LRP1) gene silencing in macrophage-like cells. LRP1 is a type 1 transmembrane receptor, which mediates ligand endocytosis and impact cell migration. This phenomenon suggested to prevent LRP1 down regulation in myeloid cells might suppress monocyte recruitment to tumors and cancer angiogenesis.
EMT biomarkers development
Yu et al. optimized microfluidic capture of CTCs with epithelial- and tumor-specific antibodies, and they then applied this technology to analyze epithelial-mesenchymal transition (EMT) in CTCs from breast cancer patients . They established quantitative, dual-colorimetric RNA-ISH assay to examine the expression of seven pooled epithelial (E) transcripts and three mesenchymal (M) transcripts in tumor cells. In their research, they found that all three major histological subtypes of invasive breast cancer (i.e. ER+/PR+ subtype; HER2+ subtype; and the ER–/PR–/HER2– triple negative subtype) contained rare tumor cells with epithelial morphology that stained with both E and M markers, while that benign breast tissue and tumor cells in pre-invasive ductal carcinoma in situ (DCIS) lesions and reactive stromal cells were exclusively epithelial or mesenchymal. By comparing CTC features in pre- and post treatment blood samples from clinical cases, they found patients who responded to therapy showed a decrease in CTC numbers and/or a proportional decrease in M + compared with E+ CTCs after treatment. In contrast, the patients who had progressive disease while on therapy showed an increased number of M+ CTCs in the post treatment samples.
Cancer diagnostic research
Payne et al. applied a probe set against mRNAs encoding cytokeratin 8, 14, 17, 18, 19 and 20, EpCAM, and MUC-1 (traditional epithelial cell markers) to detect epithelial cells and another probe set with different fluorescent color was used to detect three genes expressed in tumor cells that have undergone EMT (Twist, N-Cadherin, and fibronectin) expressed in CTCs which have undergone EMT . They found that breast cancer cells could be identified by strong pan-CK staining, whereas the surrounding PBMCs showed minimal fluorescent signals (Figure 1D). Also they found different EGFR mRNA expression levels consistent with the known EGFR protein expression status. The advance of application of fluorescence in situ hybridization technique is to detect the gene translocation. Tana et al. applied RNAscope formalin fixed paraffin embed (FFPE) assay in epithelioid hemangioendothelioma (EHE) tissue sections to detect the translocation (the chimeric WWTR1/CAMTA1 transcription factor), which would assist in the evaluation of this diagnostically challenging neoplasm as well as may represent a therapeutic target for EHE . By multispectral imaging system, WWTR1/CAMTA1 fusion transcripts presented yellow punctate dots, while wild-type WWTR1 and CAMTA1 transcripts were stained with red or green punctate dots, respectively. Among these studies, it confirms that CTCscope provides additional prognostic and predictive information in therapy monitoring.
Cancer stem cell research
Currently, In situ study, by RNAscope technology, groups of cancer stem cell biomarker was confirmed. Barry et al. applied RNAscope for Olfm4, which marks crypt base columnar (CBCs) stem cells in intestinal tissue, and to determine if intestinal stem cell (ISC) numbers was reduced by YAP (a protein known as its powerful growth-inducing and oncogenic properties) expression . And in their research, they found epithelial-specific expression of YAP suppressed intestinal cell renewal, which occurred through inhibition of the Wnt-singaling pathway. Ziskin et al. also applied multiplex fluorescent ISH and chromogenic non-isotopic ISH in 57 colorectal adenocarcinomas to detect 19 putative intestinal stem cell markers . They found the G protein-coupled receptor (lgr5) and intestinal stem cells signature gene (Ascl2) was expressed on mainly colorectal cancers, which supported the hypothesis that the cancer cells were derived from lgr5+/Ascl2+ crypt stem cells. Yan et al. applied fluorescence in situ hybridization (FISH) to detect lgr5 mRNA and genetic signature of pan- yellow fluorescent protein (YFP) expression within the Polycomb group protein (Bmi1) + clonally derived spheroids . The result indicated that the Bmi1+ ISC lineage could generate Lgr5+ cells in vitro.
On several virus infection models, CTCscope became a popular research tool for detection certain mRNA expression. In order to confirm Hamster-adapted Sin Nombre Virus (HA-SNV) replication in pulmonary endothelial cells, Safronetz et al. applied monoclonal antibodies targeting the nucleoprotein (anti-SNV NP clone 5 F1/F7) nucleotides) and polyclonal rabbit anti-CD31 antibodies in a HA-SNV infection model . They found that virus antigen was predominantly expressed in CD31-positive cells in lung tissues obtained from virus infected hamsters. Another virus research group, Ouwendijk et al. analyzed consecutive ganglionic sections in a reactivated Simian Varicella Virus (SVV) model, by ISH for SVV open reading frame 61 (ORF61) antisense RNA and IFNγ-inducible protein-10 (IP-10/CXCL10) transcripts . The abundance of T cell clusters were correlated with CXCL10 RNA, but not with those of SVV ORF61 antisense RNA. So they concluded after SVV reactivation and transient T-cell infiltration, possibly medicated by CXCL10. Recently, Bishop et al. reported the development of RNA ISH probes complementary to E6/E7 mRNA, which permits direct visualization of human papillomavirus (HPV) transcripts, in routinely processed tissues and provide an accurate HPV detection method for the clinical physicians. Besides, they found p16 expression was strongly associated with the presence of HPV E6/E7 mRNA . By comparison, they confirmed a high rate of concordance (99%) between the E6/E7 mRNA method and HPV DNA ISH.
This recently developed new technique, CTCscope, is designed for detection mRNA expression on CTCs. Due to its advantage of highly sensitivity, RNA ISH empower its high sensitivity and specificity to define low expression of commonly used biomarkers. However the future application of CTCscope from bench to bed-side seems both promising and challenged. Certain limitations of this approach may hamper its clinical use, e.g. the assay protocol which contains multiple steps is not easy to perform in a clinical lab, the changing of hybridization probes against the target mRNA may reduce the reliability of the detection, and the cut off value and clinical significance of CTC numbers need to be determined for different cancers.
Circulating tumor cells
Crypt base columnar
Ductal carcinoma in situ
Fluorescence in situ hybridization
Formalin fixed paraffin embed
Hamster-adapted Sin Nombre Virus
In situ hybridization
Intestinal stem cell
Open reading frame 61
Simian Varicella Virus.
This work was supported by Shanghai Leading Academic Discipline Project (No. B115), National Key Scientific & Technology Support Program (No. 2013BAI09B09) and Shanghai Science & Technology Committee (No. 13ZR1452400).
- Liu Z, Fusi A, Klopocki E, Schmittel A, Tinhofer I, Nonnenmacher A, Keilholz U: Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients. J Transl Med. 2011, 9: 70-10.1186/1479-5876-9-70.PubMed CentralView ArticlePubMedGoogle Scholar
- Cen P, Ni X, Yang J, Graham DY, Li M: Circulating tumor cells in the diagnosis and management of pancreatic cancer. Biochim Biophys Acta. 1826, 2012: 350-356.Google Scholar
- Eden JA: Human breast cancer stem cells and sex hormones–a narrative review. Menopause. 2010, 17: 801-810.PubMedGoogle Scholar
- Payne RE, Wang F, Su N, Krell J, Zebrowski A, Yagüe E, Ma XJ, Luo Y, Coombes RC: Viable circulating tumour cell detection using multiplex RNA in situ hybridisation predicts progression-free survival in metastatic breast cancer patients. Br J Cancer. 2012, 106: 1790-1797. 10.1038/bjc.2012.137.PubMed CentralView ArticlePubMedGoogle Scholar
- Peeters DJ, van Dam PJ, Van den Eynden GG, Rutten A, Wuyts H, Pouillon L, Peeters M, Pauwels P, Van Laere SJ, van Dam PA, Vermeulen PB, Dirix LY: Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. Br J Cancer. 2013, doi:10.1038/bjc.2013.743. [Epub ahead of print]Google Scholar
- Tewes M, Aktas B, Welt A, Mueller S, Hauch S, Kimmig R, Kasimir-Bauer S: Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat. 2009, 115: 581-590. 10.1007/s10549-008-0143-x.View ArticlePubMedGoogle Scholar
- Talasaz AH, Powell AA, Huber DE, Berbee JG, Roh KH, Yu W, Xiao W, Davis MM, Pease RF, Mindrinos MN, Jeffrey SS, Davis RW: Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci USA. 2009, 106: 3970-3975. 10.1073/pnas.0813188106.PubMed CentralView ArticlePubMedGoogle Scholar
- Lu J, Fan T, Zhao Q, Zeng W, Zaslavsky E, Chen JJ, Frohman MA, Golightly MG, Madajewicz S, Chen WT: Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int J Cancer. 2010, 126: 669-683. 10.1002/ijc.24814.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, Wu X, Vo HT, Ma XJ, Luo Y: RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn. 2012, 14: 22-29. 10.1016/j.jmoldx.2011.08.002.PubMed CentralView ArticlePubMedGoogle Scholar
- Ukpo OC, Flanagan JJ, Ma XJ, Luo Y, Thorstad WL, Lewis JS: High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma. Am J Surg Pathol. 2011, 35: 1343-1350. 10.1097/PAS.0b013e318220e59d.View ArticlePubMedGoogle Scholar
- Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S: Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013, 339: 580-584. 10.1126/science.1228522.PubMed CentralView ArticlePubMedGoogle Scholar
- Burd CE, Sorrentino JA, Clark KS, Darr DB, Krishnamurthy J, Deal AM, Bardeesy N, Castrillon DH, Beach DH, Sharpless NE: Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. Cell. 2013, 152: 340-351. 10.1016/j.cell.2012.12.010.PubMed CentralView ArticlePubMedGoogle Scholar
- Staudt ND, Jo M, Hu J, Bristow JM, Pizzo DP, Gaultier A, VandenBerg SR, Gonias SL: Myeloid cell receptor LRP1/CD91 regulates monocyte recruitment and angiogenesis in tumors. Cancer Res. 2013, 73: 3902-3912. 10.1158/0008-5472.CAN-12-4233.PubMed CentralView ArticlePubMedGoogle Scholar
- Tanas MR, Sboner A, Oliveira AM, Erickson-Johnson MR, Hespelt J, Hanwright PJ, Flanagan J, Luo Y, Fenwick K, Natrajan R, Mitsopoulos C, Zvelebil M, Hoch BL, Weiss SW, Debiec-Rychter M, Sciot R, West RB, Lazar AJ, Ashworth A, Reis-Filho JS, Lord CJ, Gerstein MB, Rubin MA, Rubin BP: Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med. 2011, 3: 98ra82-View ArticlePubMedGoogle Scholar
- Barry ER, Morikawa T, Butler BL, Shrestha K, de la Rosa R, Yan KS, Fuchs CS, Magness ST, Smits R, Ogino S, Kuo CJ, Camargo FD: Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature. 2013, 493: 106-110.PubMed CentralView ArticlePubMedGoogle Scholar
- Ziskin JL, Dunlap D, Yaylaoglu M, Fodor IK, Forrest WF, Patel R, Ge N, Hutchins GG, Pine JK, Quirke P, Koeppen H, Jubb AM: In situ validation of an intestinal stem cell signature in colorectal cancer. Gut. 2012, 62: 1012-1023.View ArticlePubMedGoogle Scholar
- Yan KS, Chia LA, Li X, Ootani A, Su J, Lee JY, Su N, Luo Y, Heilshorn SC, Amieva MR, Sangiorgi E, Capecchi MR, Kuo CJ: The intestinal stem cell markers Bmi1 and Lgr5 identify two functionally distinct populations. Proc Nati Acad Sci. 2012, 109: 466-471. 10.1073/pnas.1118857109.View ArticleGoogle Scholar
- Safronetz D, Prescott J, Haddock E, Scott DP, Feldmann H, Ebihara H: Hamster-adapted Sin Nombre virus causes disseminated infection and efficiently replicates in pulmonary endothelial cells without signs of disease. J Virol. 2013, 87: 4778-4782. 10.1128/JVI.03291-12.PubMed CentralView ArticlePubMedGoogle Scholar
- Ouwendijk WJ, Abendroth A, Traina-Dorge V, Getu S, Steain M, Wellish M, Andeweg AC, Osterhaus AD, Gilden D, Verjans GM, Mahalingam R: T-cell infiltration correlates with CXCL10 expression in ganglia of cynomolgus macaques with reactivated simian varicella virus. J Virol. 2013, 87: 2979-2982. 10.1128/JVI.03181-12.PubMed CentralView ArticlePubMedGoogle Scholar
- Bishop JA, Ma XJ, Wang H, Luo Y, Illei PB, Begum S, Taube JM, Koch WM, Westra WH: Detection of transcriptionally active high-risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method. Am J Surg Pathol. 2012, 36: 1874-1882. 10.1097/PAS.0b013e318265fb2b.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.